1. Home
  2. MDRR vs CTXR Comparison

MDRR vs CTXR Comparison

Compare MDRR & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MDRR

Medalist Diversified REIT Inc.

N/A

Current Price

$11.36

Market Cap

18.3M

Sector

Real Estate

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.54

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDRR
CTXR
Founded
2015
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.3M
18.9M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
MDRR
CTXR
Price
$11.36
$0.54
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
1.5K
612.5K
Earning Date
03-02-2026
05-12-2026
Dividend Yield
2.43%
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.47
$0.48
52 Week High
$14.52
$2.24

Technical Indicators

Market Signals
Indicator
MDRR
CTXR
Relative Strength Index (RSI) 53.20 39.91
Support Level $11.26 $0.48
Resistance Level $12.20 $0.74
Average True Range (ATR) 0.44 0.05
MACD 0.03 -0.00
Stochastic Oscillator 73.36 3.66

Price Performance

Historical Comparison
MDRR
CTXR

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: